Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

14-08-2018 | Original Paper

A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism

Auteurs: Michael Chez, Shawn Kile, Christopher Lepage, Carol Parise, Bobbie Benabides, Andrea Hankins

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 5/2020

Abstract

Prior studies have demonstrated successful irritability treatment using dopaminergic antagonists in autistic patients. The purpose of this pilot study was to assess the effect of dextromethorphan/quinidine (DM/Q) in autistic adults (18–60 years of age). This was a randomized, blinded, crossover, study of 14 patients randomized to DM/Q or a placebo for 8 weeks, washed out for 4 weeks, then crossed over to the opposite treatment. There were no serious adverse events. Subjects were significantly lower on the Aberrant Behavioral Checklist for Irritability (ABC-IR) (F_1,10 = 7.42; p = 0.021). Improvements in aggression and Clinical Global Impression were also seen. The findings suggest that DM/Q is well-tolerated and associated with improvements in irritability and aggression in adults with autism.

vorige artikel Parent and Teacher Reports of Comorbid Anxiety and ADHD Symptoms in Children with ASD

volgende artikel Working with Dual Diagnoses: A Survey of Teachers Serving Deaf or Hard of Hearing Children Who Have Autism Spectrum Disorder

Aman, M., Rettiganti, M., Nagaraja, H. N., Hollway, J. A., McCracken, J., McDougle, C. J., et al. (2015). Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology, 25(6), 482–493. https://doi.org/10.1089/cap.2015.0005.CrossRefPubMedPubMedCentral

Baio, J., Wiggins, L., Christensen, D. L., Maenner, M. J., Daniels, J., Warren, Z., et al. (2018). Prevalence of autism spectrum disorder among children aged 8 years—Autism and developmental disabilities monitoring network, 11 sites, United States, 2014. MMWR Surveillance Summaries, 67(6), 1–23. https://doi.org/10.15585/mmwr.ss6706a1.CrossRefPubMedCentral

Bauman, M., & Kemper, T. L. (1985). Histoanatomic observations of the brain in early infantile autism. Neurology, 35(6), 866–874.CrossRef

Bauman, M. L., & Kemper, T. L. (1994). The neurobiology of autism. Baltimore: Johns Hopkins University Press.

Chez, M. G., Burton, Q., Dowling, T., Chang, M., Khanna, P., & Kramer, C. (2007). Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. Journal of Child Neurology, 22(5), 574–579.CrossRef

Hammond, F. M., Alexander, D. N., Cutler, A. J., D’Amico, S., Doody, R. S., Sauve, W., et al. (2016). PRISM II: An open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurology, 16, 89. https://doi.org/10.1186/s12883-016-0609-0.CrossRefPubMedPubMedCentral

Hellings, J. A., Nickel, E. J., Weckbaugh, M., McCarter, K., Mosier, M., & Schroeder, S. R. (2005). The overt aggression scale for rating aggression in outpatient youth with autistic disorder: Preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences, 17(1), 29–35.CrossRef

IBM SPSS Statistics for Windows, (2012). vol 21.0. Armonk: IBM Corp.

King, B. H., Wright, D. M., Handen, B. L., Sikich, L., Zimmerman, A. W., McMahon, W., et al. (2001). Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 40(6), 658–665.CrossRef

Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119. https://doi.org/10.1097/CHI.0b013e3181b76658.CrossRefPubMed

Margari, L., Matera, E., Craig, F., Petruzzelli, M. G., Palmieri, V. O., Pastore, A., et al. (2013). Tolerability and safety profile of risperidone in a sample of children and adolescents. International Clinical Psychopharmacology, 28(4), 177–183. https://doi.org/10.1097/YIC.0b013e328362497b.CrossRefPubMed

McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314–321. https://doi.org/10.1056/NEJMoa013171.CrossRefPubMed

Orsolini, L., Tomasetti, C., Valchera, A., Vecchiotti, R., Matarazzo, I., Vellante, F., et al. (2016). An update of safety of clinically used atypical antipsychotics. Expert Opinion on Drug Safety, 15(10), 1329–1347. https://doi.org/10.1080/14740338.2016.1201475.CrossRefPubMed

Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124(6), 1533–1540.CrossRef

Pattee, G. L., Wymer, J. P., Lomen-Hoerth, C., Appel, S. H., Formella, A. E., & Pope, L. E. (2014). An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Current Medical Research and Opinion, 30(11), 2255–2265. https://doi.org/10.1185/03007995.2014.940040.CrossRefPubMedPubMedCentral

Perry, E. K., Lee, M. L., Martin-Ruiz, C. M., Court, J. A., Volsen, S. G., Merrit, J., et al. (2001). Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain. American Journal of Psychiatry, 158(7), 1058–1066.CrossRef

Pioro, E. P. (2014). Review of dextromethorphan 20 mg/quinidine 10 mg (NUEDEXTA((R))) for pseudobulbar affect. Neurology and Therapy, 3(1), 15–28. https://doi.org/10.1007/s40120-014-0018-5.CrossRefPubMedPubMedCentral

Posey, D. J., Kem, D. L., Swiezy, N. B., Sweeten, T. L., Wiegand, R. E., & McDougle, C. J. (2004). A pilot study of D-cycloserine in subjects with autistic disorder. American Journal of Psychiatry, 161(11), 2115–2117.CrossRef

Purcell, A. E., Jeon, O. H., Zimmerman, A. W., Blue, M. E., & Pevsner, J. (2001). Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology, 57(9), 1618–1628.CrossRef

Schreibman, L. (2000). Intensive behavioral/psychoeducational treatments for autism: Research needs and future directions. Journal of Autism Developmental Disorders, 30(5), 373–378.CrossRef

Woodard, C., Groden, J., Goodwin, M., & Bodfish, J. (2007). A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism. Autism, 11(1), 29–41. https://doi.org/10.1177/1362361307070989.CrossRefPubMed

Woodard, C., Groden, J., Goodwin, M., Shanower, C., & Bianco, J. (2005). The treatment of the behavioral sequelae of autism with dextromethorphan: A case report. Journal of Autism Developmental Disorders, 35(4), 515–518. https://doi.org/10.1007/s10803-005-5041-z.CrossRefPubMed

Zimmerman, A. (1991). Treating autism and other developmental disorders in children with NMDA receptor antagonists. Patent 4,994,467. https://patentimages.storage.googleapis.com/b7/68/af/6bd5da44812183/US4994467.pdf.

Titel: A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism
Auteurs: Michael Chez
Shawn Kile
Christopher Lepage
Carol Parise
Bobbie Benabides
Andrea Hankins
Publicatiedatum: 14-08-2018
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 5/2020
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-018-3703-x

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 5/2020

Speaking the Same Language? A Preliminary Investigation, Comparing the Language and Communication Skills of Females and Males with High-Functioning Autism

Longitudinal Epidemiological Study of Autism Subgroups Using Autism Treatment Evaluation Checklist (ATEC) Score

Everything has Its Time: Narrow Temporal Windows are Associated with High Levels of Autistic Traits Via Weaknesses in Multisensory Integration

Brief Report: Implementation of a Specific Carbohydrate Diet for a Child with Autism Spectrum Disorder and Fragile X Syndrome

Working with Dual Diagnoses: A Survey of Teachers Serving Deaf or Hard of Hearing Children Who Have Autism Spectrum Disorder

Success Factors Enabling Employment for Adults on the Autism Spectrum from Employers’ Perspective